Scholar Rock
Clinical-stage biopharmaceutical company developing innovative medicines by modulating protein growth factors to treat serious diseases including spinal muscular atrophy and other rare diseases. Publicly traded on NASDAQ (SRRK).
Notes
Scholar Rock is a clinical-stage biopharmaceutical company focused on developing innovative medicines by modulating protein growth factors. The company is publicly traded on NASDAQ under the ticker symbol SRRK and is headquartered in Cambridge, Massachusetts.
The company's approach targets the activation of latent growth factors, particularly in the TGF-beta superfamily, to treat diseases where these proteins play a fundamental role. Their lead program apitegromab targets myostatin for the treatment of spinal muscular atrophy (SMA).
Scholar Rock's platform enables selective modulation of growth factor signaling, potentially offering more targeted therapeutic effects with improved safety profiles compared to traditional approaches.
Team
- Jay Backstrom, M.D., M.P.H. - President & Chief Executive Officer
- LinkedIn: linkedin.com/in/jaybackstrom
- Timothy Pearson - Chief Financial Officer
- Yung Chyung, M.D. - Chief Medical Officer
- Nagesh Mahanthappa, Ph.D. - Co-founder
Additional Research Findings
- NASDAQ: SRRK (publicly traded)
- Portfolio company of Polaris Partners
- Focus on protein growth factor modulation
- Lead program: Apitegromab for spinal muscular atrophy (SMA)
- TGF-beta superfamily targeting platform
- Cambridge, Massachusetts headquarters
- Founded in 2012
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Polaris Partners | US | biotech-focused | - | 33 |